Initial treatment following transformed lymphoma
| Treatment . | n (%) . |
|---|---|
| Rituximab + chemotherapy | 131 (34.6) |
| Rituximab monotherapy | 98 (25.9) |
| Radiation | 26 (6.9) |
| Chemotherapy | 25 (6.6) |
| RIT | 16 (4.2) |
| Investigational therapy | 16 (4.2) |
| Stem cell transplantation | 6 (1.8) |
| Combined modality: radiation | 5 (1.3) |
| Other noninvestigational therapy | 1 (0.3) |
| None | 55 (14.5) |
| Treatment . | n (%) . |
|---|---|
| Rituximab + chemotherapy | 131 (34.6) |
| Rituximab monotherapy | 98 (25.9) |
| Radiation | 26 (6.9) |
| Chemotherapy | 25 (6.6) |
| RIT | 16 (4.2) |
| Investigational therapy | 16 (4.2) |
| Stem cell transplantation | 6 (1.8) |
| Combined modality: radiation | 5 (1.3) |
| Other noninvestigational therapy | 1 (0.3) |
| None | 55 (14.5) |
RIT, radioimmunotherapy.